Movement Alert|SELLAS Life Sciences Group Inc. Intraday Rise 7.83%, Phase 3 AML Win and Target Price Increase Support Rebound

Market Focus11-18 22:31

On November 18, SELLAS Life Sciences Group Inc. rose 7.83% in Regular Trading, trading at $19.415 per share, with turnover of $51.1558 million.

The move coincided with continued market repricing after the company reported that galinpepimut-S met the primary endpoint in the Phase 3 REGAL trial in acute myeloid leukemia, while a brokerage also raised its price target to $40 from $30.

Earlier disclosures showed median overall survival of 24 months for treated patients versus 14.7 months for the control arm, with a 41% reduction in risk of death and no new safety issues. The company said it plans to discuss an accelerated filing strategy with the FDA and prepare a marketing application in H1 2027. Although SELLAS Life Sciences Group Inc. also announced a $150 million underwritten public offering, with an additional $22.5 million option for underwriters, the latest intraday rise suggests investors are refocusing on the Phase 3 clinical milestone.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment